Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Hodgkin’s lymphoma therapy improves survival in hard-to-treat cases

Brentuximab vedotin — an antibody attached to a chemotherapy drug — improved progression-free survival to a median of 43 months versus 24 months with placebo.

Hodgkin’s lymphoma therapy improves survival in hard-to-treat cases. CT image of 46 year old patient with Hodgkin's lymphoma, image at neck height

Source: JHeuser / Wikimedia Commons

CT image of a patient with Hodgkin’s lymphoma

Brentuximab vedotin (BV) has shown “remarkable” efficacy when used after autologous stem-cell transplantation in patients with difficult-to-treat Hodgkin’s lymphoma.

Results of the phase III AETHERA trial, published in The Lancet[1] on 19 March 2015, show that BV — an antibody attached to a chemotherapy drug — improved progression-free survival to a median of 43 months versus 24 months with placebo.

“The bottom line is that BV is a very effective drug in poor-risk Hodgkin’s lymphoma and it spares patients from the harmful effects of further traditional chemotherapy by breaking down inside the cell resulting in less toxicity,” says lead author Craig Moskowitz, from Memorial Sloan Kettering Cancer Center, New York. “No medication available today has had such dramatic results in patients with hard-to-treat Hodgkin’s lymphoma.”

BV consists of an anti-CD30 antibody conjugated to a microtubule-disrupting drug, monomethyl auristatin E. Developed jointly by Seattle Genetics and Takeda, BV (marketed as Adcetris) has been approved for use in relapsed or refractory Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma in 50 countries worldwide, including the United States in August 2011 and across Europe in October 2012.

In the AETHERA trial, 329 patients with unfavourable-risk relapsed or refractory Hodgkin’s lymphoma who had undergone autologous stem-cell transplantation were randomly assigned to receive 16 cycles of BV 1.8 mg/kg or placebo intravenously every three weeks.

The primary endpoint — progression-free survival — was significantly improved with active treatment versus placebo, with a hazard ratio of 0.57 (95% confidence interval [CI] 0.40–0.81; P=0.0013). At two years, progression-free survival was 63% (95% CI 55–70) with BV versus 51% (95% CI 43–59) with placebo. The three-year rate of overall survival exceeded 80%, which the researchers describe as “remarkable”.

The significant benefit of BV was consistent across clinically important subgroups, including primary refractory patients, patients who had relapsed within 12 months of first-line therapy and patients who relapsed after 12 months.

The most frequent adverse events in the BV group were peripheral sensory neuropathy (56% with BV versus 16% with placebo) and neutropenia (35% vs 12%). Most patients with BV-associated neuropathy experienced a resolution or improvement in symptoms with a median time to improvement of 23.4 weeks. At the time of analysis, 17% of patients had died in the BV group compared with 16% in the placebo group.

Writing in a linked comment article[2], Andreas Engert, from University Hospital of Cologne, Germany, highlights the current poor prognosis and lack of treatment options for patients who relapse after autologous stem-cell transplantation. The results “clearly show” that consolidation therapy with BV after transplantation improves the prognosis of Hodgkin’s lymphoma patients, he says.

“AETHERA is a positive study establishing a promising new treatment approach for patients with Hodgkin’s lymphoma at high risk for relapse,” says Engert. “We look forward to a better definition of patients with relapsed Hodgkin’s lymphoma who should receive consolidation treatment with BV.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068201

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.